Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Hengrui (恒瑞医药) A/H Listing: A Worthy Comparison with Hansoh Pharma

Foshan Haitian Flavouring A/H Listing - Strong Brand but Sales Have Been Slowing Down

Jiangsu Hengrui Pharma A/H Listing - Innovation and Overseas Expansion Driving Earnings Rebound

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jiangsu Hengrui Pharmaceuticals / Equity Capital Markets

Jiangsu Hengrui Pharmaceuticals (1276 HK)

<ul>
<li>Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.</li>
<li>Given its similarity to Hong Kong-listed Hansoh Pharma, had done a comparison between the two.</li>
<li>In this note, we looked at the latest results releases from both companies and highlighted granular differences. It is also interesting to compare the relative valuation from a historical perspective.</li>
</ul>


Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
Given its similarity to Hong Kong-listed Hansoh Pharma, had done a comparison between the two.
In this note, we looked at the latest results releases from both companies and highlighted granular differences. It is also interesting to compare the relative valuation from a historical perspective.


Hengrui (恒瑞医药) A/H Listing: An Updated Comparison with Hansoh